Ulrich-Merzenich Gudrun, Panek D, Zeitler H, Vetter H, Wagner H
Medical Policlinic of the Rheinische Friedrich-Wilhelms-University of Bonn, Wilhelmstr. 35-37, D-53111 Bonn, Germany.
Indian J Exp Biol. 2010 Mar;48(3):208-19.
Drug development in phytomedicine has been focused in the past on the discovery and analysis of new structures from natural products. The search aimed at the determination of the single "active principle" in plants, based on the assumption that a plant has one or a few ingredients which determine its therapeutic effects. But traditional systems of medicines like Ayurveda, traditional Chinese medicine or the European phytotherapy generally assume that a synergy of all ingredients of the plants will bring about the maximum of therapeutic efficacy. This approach has for long been impossible to investigate since adequate methods to standardize complex plant mixtures as well as to rationalize complex mode of actions were lacking. The introduction of high throughput technologies provides the opportunity to determine profiles of plants and to systematically explore the mode of action of combinatory drug regimes. The present review highlights the concept of synergy and gives examples of synergistic effects of plant constituents. It elaborates on how the high throughput technologies can be used in drug development from natural products with the aim of creating evidence-based plant medications in prevention and treatment of different diseases in the form of new single treatments or new combinatory drug regimes while exploiting synergy-effects.
过去,植物药的药物研发主要集中在从天然产物中发现和分析新结构。这种探索旨在确定植物中的单一“活性成分”,其依据的假设是植物具有一种或几种决定其治疗效果的成分。但像阿育吠陀医学、传统中医或欧洲植物疗法等传统医学体系通常认为,植物所有成分的协同作用将带来最大的治疗功效。长期以来,由于缺乏标准化复杂植物混合物以及使复杂作用模式合理化的适当方法,这种方法一直无法进行研究。高通量技术的引入提供了确定植物概况并系统探索联合用药方案作用模式的机会。本综述强调了协同作用的概念,并给出了植物成分协同效应的例子。它阐述了如何将高通量技术用于天然产物的药物研发,目的是以新的单一疗法或新的联合用药方案的形式,在利用协同效应的同时,创建基于证据的植物药物,用于预防和治疗不同疾病。